Literature DB >> 17123805

Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice.

Martina Hesse1, Leopold F Fröhlich, Ute Zeitz, Beate Lanske, Reinhold G Erben.   

Abstract

To explore further the role of the vitamin D axis for fibroblast growth factor-23 (FGF23) signaling, we mated Fgf-23 deficient (Fgf-23(-/-)) mice and vitamin D receptor (VDR) mutant mice with a non-functioning VDR. To prevent secondary hyperparathyroidism in VDR and compound mutant mice, all mice were kept on a rescue diet enriched with calcium, phosphorus, and lactose. Consistent with previous findings, Fgf-23(-/-) animals showed hypercalcemia, hyperphosphatemia, growth retardation, ectopic calcifications, severe osteoidosis, skin atrophy, and renal dysfunction. In addition, here we describe that Fgf-23(-/-) mice are hypoglycemic, and have profoundly increased peripheral insulin sensitivity and improved subcutaneous glucose tolerance, but normal renal expression of the aging suppressor gene Klotho. Although VDR and double mutants on the rescue diet still had moderately elevated parathyroid hormone serum levels and lower bone mineral density compared to wild-type mice, double mutant mice were normocalcemic and normophosphatemic, and had normal body weight, normal renal function, and no ectopic calcifications. Ablation of vitamin D signaling in compound mutants also normalized subcutaneous glucose tolerance tests and insulin secretory response. In conclusion, our results indicate that the alterations in mineral and carbohydrate metabolism present in Fgf-23(-/-) mice require an intact vitamin D signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123805     DOI: 10.1016/j.matbio.2006.10.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  78 in total

Review 1.  The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

Authors:  Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

Review 2.  Is 24,25(OH)D level really high in dialysis patients with high FGF23 levels?

Authors:  Hulya Taskapan
Journal:  Int Urol Nephrol       Date:  2012-03-31       Impact factor: 2.370

3.  Ablation of systemic phosphate-regulating gene fibroblast growth factor 23 (Fgf23) compromises the dentoalveolar complex.

Authors:  E Y Chu; H Fong; F A Blethen; K A Tompkins; B L Foster; K D Yeh; K J Nagatomo; D Matsa-Dunn; D Sitara; B Lanske; R B Rutherford; M J Somerman
Journal:  Anat Rec (Hoboken)       Date:  2010-07       Impact factor: 2.064

Review 4.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 5.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 6.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

Review 7.  Klotho and aging.

Authors:  Makoto Kuro-o
Journal:  Biochim Biophys Acta       Date:  2009-02-20

8.  The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study.

Authors:  Benjamin D Parker; Leon J Schurgers; Cees Vermeer; Nelson B Schiller; Mary A Whooley; Joachim H Ix
Journal:  Atherosclerosis       Date:  2009-11-22       Impact factor: 5.162

9.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

Review 10.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.